Silo pharma announces closing of $2 million public offering

Sarasota, fl, may 16, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series a-1 warrants (“series a-1 warrants”) to purchase up to 3,333,338 shares of common stock and series a-2 warrants (“series a-2 warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated series a-1 warrant and series a-2 warrant. the series a-1 warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire five years thereafter. the series a-2 warrants have an exercise price of $0.60 per share, are exercisable upon issuance and expire eighteen months thereafter.
SILO Ratings Summary
SILO Quant Ranking